Michigan Initial Experience Using Tigertriever for Thrombectomy (MIGHTY)
Status
Conditions
Treatments
Details and patient eligibility
About
The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.
Full description
You have been asked to take part in a research study because you have recently been admitted for large vessel occlusion (LVO) and are being treated by Tigertriever.
The treatment is a standard of care (SOC), and if you agree to take part in this study, your participation will include an additional study visit after 3 months. Your study visit will take place at Henry Ford Hospital Neurology or respective collaborator.
For some research studies, such as the one you are being asked to join, it is important that you do not learn the results of certain tests. Whether you intend it or not, sometimes learning this information may make you change your actions and behaviors in ways that could impact the outcome of the study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.
- Tigertriever was used as the first line treatment in the target vessel.
- A signed informed consent.
- Age ≥ 18.
Exclusion criteria
-1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.
3. pre-stroke disability (pre-stroke mRS ≥ 2).
Trial design
150 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Kelly Tundo, RN; Alex Chebl, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal